Form 4: Pasithea Director Lawrence Steinman Awarded Stock Options

Pasithea Therapeutics Director Lawrence Steinman received a grant of 242,913 stock options with an exercise price of $0.715, vesting over one year.

Summary

• Lawrence Steinman, a Director of Pasithea Therapeutics Corp. (KTTA), was granted 242,913 stock options.
• The options have an exercise price of $0.715 per share.
• The grant date for these options was October 24, 2025.
• The options will vest in full upon the one-year anniversary of the grant date, provided Mr. Steinman remains a director.
• Full vesting will also occur upon a Change in Control, as defined in the Issuer's 2023 Stock Incentive Plan.
• The expiration date for these stock options is October 23, 2035.
• Following this transaction, Mr. Steinman beneficially owns 242,913 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options is a routine compensation event that generally aligns director interests with shareholders, indicating a stable governance structure. It is not a direct indicator of operational performance but rather a standard incentive mechanism.

Positives

• The stock option grant aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The grant is made under the Issuer's 2023 Stock Incentive Plan, indicating a structured approach to executive and director compensation.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity.

Risks

• The options' value is contingent on the company's stock price exceeding the exercise price of $0.715.
• Vesting is conditional on the reporting person remaining a director for one year from the grant date, posing a risk of forfeiture if employment terms change.

Future Outlook

The options are set to vest in full upon the one-year anniversary of the grant date, contingent on the director's continued service, or immediately upon a Change in Control.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to incentivize leadership and align their interests with long-term shareholder value creation. This type of compensation is a standard component of executive and director remuneration packages.

Comparison to Industry Standards

• Stock option grants are a standard form of non-cash compensation for directors and executives across various industries, including biotechnology. The specific number of options and exercise price would typically be benchmarked against peer companies of similar size and stage of development, though no specific comparable companies or projects are mentioned in the filing.
• The vesting schedule, with full vesting after one year or upon a change in control, is a common structure designed to retain key personnel and provide immediate incentives during strategic events.

Corporate Governance

Related Party Transactions

• The grant of stock options to Lawrence Steinman, a Director of Pasithea Therapeutics Corp., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Lawrence Steinman): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance and long-term value creation.

Next Steps

• The options will vest on October 24, 2026, provided the director remains in their role.
• The director may exercise the options at any time after vesting and before the expiration date of October 23, 2035.

Key Dates

Recommendation

This filing reports a routine compensation event for a director, specifically a stock option grant. While it aligns the director's interests with shareholders and is a positive for corporate governance, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard practice and does not significantly alter the investment thesis for Pasithea Therapeutics Corp.

Keywords

Pasithea Therapeutics, KTTA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Vesting